ReviewRegenerative therapy2025
Blood derivatives as monotherapy and combination therapy: A promising strategy for wound healing.
Review in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wound healing is a highly orchestrated biological process, and any disruption or delay in its progression can result in the formation of chronic wounds. Such conditions impose a considerable clinical and socioeconomic burden on both patients and healthcare systems. Over the years, numerous therapeutic strategies have been investigated to promote tissue repair, with varying degrees of success. Among these, blood-derived products have emerged as a focal point of interest, owing to their regenerative potential and bioactive composition. Preparations including platelet-rich plasma, platelet-rich fibrin, platelet lysates, and autologous conditioned serum have demonstrated the capacity to enhance healing through the delivery of concentrated growth factors and cytokines. Each derivative possesses distinct advantages and limitations determined by its cellular content, biomolecular profile, and method of preparation. Most commonly presented in liquid or gel form, these products can be applied to diverse wound types and tailored to specific treatment protocols. Their use may be autologous or allogeneic, and they can be employed alone or in combination with other therapeutic modalities to achieve synergistic effects. This review provides a comprehensive overview of the characteristics, preparation techniques, biochemical composition, and clinical efficacy of various blood derivatives, underscoring their value either as standalone interventions or as part of multimodal regimens in advancing wound healing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.